Beckman Coulter and Quidel settle litigation

July 28, 2021

Beckman Coulter and Quidel announced a settlement agreement to end litigation that began in November 2017, following Quidel's acquisitions of the BNP Business from Alere.

Under the agreement, Beckman Coulter has obtained all rights of manufacture, distribution and sale of a BNP assay for Beckman Coulter analyzers, fully resolving the dispute. Quidel will continue to manufacture and supply some components to Beckman Coulter related to the assay, and Beckman Coulter will exclusively sell and manufacture to customers the TRIAGE BNP by Quidel under the brand name Access BNP. Quidel will receive $70-$75 million per year through 2029.

BNP is a protein biomarker secreted by the ventricular musculature in response to volume or pressure overload on the heart. The biomarker can be used in the diagnosis of heart failure and left ventricular dysfunction.

Visit Beckman Coulter for more news

Photo 80414627 © Alexey Novikov |
Dreamstime Xxl 80414627 (1)
Photo 2783123 © Pmisak |
Dreamstime Xxl 14016195
Photo by Karolina Grabowska:
Pexels Money Pexels Karolina Grabowska 4386368
Pixabay Mobile Devices 2017978
Pixabay Money Banknotes Gbdb3efe4b 1280